Lisata Therapeutics Inc. Common Stock (LSTA)
Stock · NASDAQ · Health Care
$1.07as of 10/16/2026
Price chart
Active signals
LSTA Signal Track Record
How signals performed across all stocks →What LSTA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -4.7% | 30% | October 8, 2026 |
| Bollinger Band Breakout | 27 | -4.2% | 33% | August 21, 2026 |
| Bollinger Band Breakdown | 25 | -2.5% | 44% | October 5, 2026 |
| 200-Day Moving Average TouchActive now | 21 | -4.8% | 33% | July 7, 2026 |
| Any 20-session window (baseline) | -1.8% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LSTA
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cance…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 21
- Website
- www.lisata.com/
Fundamentals
- 1-day range
- $1.02$1.05
- Market cap
- $9.74M
- P/E (trailing)
- —
- P/E (forward)
- -0.88
- EPS (trailing)
- $-1.14
- Dividend yield
- —
- Beta
- 0.97
- Avg. volume
- 306.4K
How Lisata Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Feb 27, 2025 · via SEC EDGAR / Finnhub
Lisata Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LSTALisata Therapeutics Inc. Common Stock$1.03▼ 3.74%Market cap $9.74MP/E —$0.98$5.07
- GDTCCytoMed Therapeutics Limited Ordinary Shares$0.88▲ 1.15%Market cap $9.50MP/E —$0.6801$3.68
- BIVIBioVie Inc. Class A Common Stock$1.2▲ 6.19%Market cap $10.18MP/E —$0.82$3.79
- ADILAdial Pharmaceuticals Inc Common Stock$3.49▲ 11.15%Market cap $10.29MP/E —$1.31$232.5
- QNRXQuoin Pharmaceuticals Ltd. American Depositary Shares$3.9▼ 3.23%Market cap $9.18MP/E —$3.25$23.5
- TOVXTheriva Biologics Inc. Common Stock$0.21▲ 0.00%Market cap $10.32MP/E —$0.1628$0.8632
- ASBPAspire Biopharma Holdings Inc. Common Stock$8.78▲ 1.62%Market cap $9.14MP/E —$3.31$562.8
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LSTA Lisata Therapeutics Inc. Common Stock | $9.74M | — | $1.03 | ▼ 3.74% | $0.98$5.07 |
| GDTC CytoMed Therapeutics Limited Ordinary Shares | $9.50M | — | $0.88 | ▲ 1.15% | $0.6801$3.68 |
| BIVI BioVie Inc. Class A Common Stock | $10.18M | — | $1.2 | ▲ 6.19% | $0.82$3.79 |
| ADIL Adial Pharmaceuticals Inc Common Stock | $10.29M | — | $3.49 | ▲ 11.15% | $1.31$232.5 |
| QNRX Quoin Pharmaceuticals Ltd. American Depositary Shares | $9.18M | — | $3.9 | ▼ 3.23% | $3.25$23.5 |
| TOVX Theriva Biologics Inc. Common Stock | $10.32M | — | $0.21 | ▲ 0.00% | $0.1628$0.8632 |
| ASBP Aspire Biopharma Holdings Inc. Common Stock | $9.14M | — | $8.78 | ▲ 1.62% | $3.31$562.8 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Lisata Therapeutics wins new US patent for pancreatic cancer drugYahoo · 10/8/2026
- Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid TumorsYahoo · 10/8/2026
- Lisata Therapeutics Granted US Patent: Methods For Treating Pancreatic Cancer And Other Solid Tumorsbenzinga · 10/6/2026
- Lisata subsidiary Marea treats first patient in MAR002 acromegaly trialYahoo · 10/5/2026
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of AcromegalyYahoo · 10/5/2026
- MARKETS LIVE: US futures dip amid Fed and oil uncertaintyYahoo · 10/5/2026
- Lisata’s Marea Therapeutics Announces First Patient Dosed In Its Phase 2 Clinical Trial Of MAR002 For Treatment Of AcromegalyBenzinga · 10/5/2026
- Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific SessionsYahoo · 9/24/2026
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026Yahoo · 9/24/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 1.02M
- Total value held
- $4.88M
- Institutional holders
- 33
- Unknown271.8K
- Unknown131.7K
- Unknown90.0K
- Unknown75.0K
- Unknown70.9K
- Unknown61.9K
- Unknown54.9K
- Unknown47.5K
- Unknown42.2K
- Unknown31.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Lisata reports first patient dose in MAR002 acromegaly trial
Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.
Lisata reports first patient dose in MAR002 acromegaly trial. Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.